You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Valmet Q1'24: The glass is half full
Our analyst Antti Viljakainen comments on Valmet's Q1 and our valuation and recommendation for the company at the moment!
Content:
00:00 Intro
00:11 Why was Valmet's Q1 neutral in our view
01:39 Differences between segments
03:02 Drop in order intake
03:42 Order intake's conversion to revenue
04:56 Valuation and recommendation
Read the latest research report:
The Glass is half full , published 2024-05-06
Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024
Aiforia as an Investment | Life Science Night Dec. 2, 2024
Faron Pharmaceuticals as an Investment | Life Science Night Dec. 2, 2024
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Life Science Night | December 2, 2024
Titta på alla videor